SH-ZCCDD-RGB
Zane Cohen Centre for Digestive Diseases
Donate

We build knowledge to improve treatment

caring for you and your family

Learn More
Clinical Trial for a New Medication in Ulcerative Colitis

Details of Research

Contact:
Shlomit Boguslavsky, Clinical Research Coordinator
416-586-4800 ext. 4989
Shlomit.Boguslavsky@sinaihealth.ca

Primary Investigator: Dr. Hillary Steinhart

Enrolment: Ongoing

Mount Sinai Hospital is participating in a research study to understand the safety and effectiveness of an investigational medication for treating Ulcerative colitis.

We are looking for individuals:

  • With Ulcerative colitis.
  • Experiencing symptoms related to their Ulcerative colitis.
  • Have previously and/or currently not responded to one or more of the following treatments:
    - Biologic Therapy (e.g., infliximab (Remicade), adalimumab (Humira), vedolizumab (Entyvio), golimumab (Simponi), tofacitinib (Xeljanz)   

Description of Clinical Trial:

This study will last up to 40 weeks. Your Ulcerative colitis will be assessed and, if eligible, participants will be receive study medication. There is not a placebo component to this study placebo ("dummy" drug). All drug is open label.  Reimbursement will be provided for study-related travel expenses.